What Are the Contraindications for ACE Inhibitors?

ACE inhibitors are among the most widely prescribed drug classes in cardiovascular medicine, but they come with a well-defined list of situations where they should not be used at all or should be used only with extreme caution. The absolute contraindications include a history of angioedema related to ACE inhibitors, pregnancy, and bilateral renal artery stenosis. Beyond those clear-cut prohibitions, several other conditions and drug combinations create serious enough risks that prescribers treat them as near-absolute barriers to use.

Angioedema Is the Most Dangerous Absolute Contraindication

If you have ever experienced angioedema while taking an ACE inhibitor, you should never take one again. Angioedema is a rapid swelling of the deeper layers of the skin, most often affecting the lips, tongue, throat, and airways. When it involves the throat, it can obstruct breathing and become life-threatening within minutes. The mechanism behind it is well understood: ACE inhibitors block the breakdown of a substance called bradykinin, which normally gets degraded by the same enzyme the drug is designed to inhibit. That buildup of bradykinin can trigger sudden, severe tissue swelling in susceptible people.

A national chart review conducted across the US Veterans Affairs health care system found that about 0.20% of people who started an ACE inhibitor developed angioedema while taking the medication.¹ That sounds small, but given how many millions of people take these drugs, it translates to a substantial number of cases each year. And because the reaction can recur unpredictably and escalate in severity, even a single episode makes re-exposure too risky.

This contraindication also extends to drugs closely related to ACE inhibitors. Sacubitril/valsartan, a combination drug used in heart failure, is specifically contraindicated in anyone with a history of angioedema because the sacubitril component also inhibits bradykinin breakdown through a related pathway.²

Pregnancy

ACE inhibitors are contraindicated in pregnancy. The risk is clearest during the second and third trimesters, when these drugs can cause fetal kidney shutdown, low amniotic fluid, skull malformations, and even fetal death. The fetal kidneys are particularly vulnerable because angiotensin II plays a critical role in maintaining blood flow through the developing kidney, and blocking it with an ACE inhibitor compromises that system at a critical stage of development.

For a long time, the first trimester was thought to be relatively safer, but more recent evidence has muddied that picture. Research has suggested an increased risk of birth defects even after first-trimester exposure to ACE inhibitors in women being treated for hypertension.³ Because of this, the practical guidance is straightforward: if you are pregnant or planning to become pregnant, ACE inhibitors should be stopped and replaced with a safer alternative. Women of childbearing age who are prescribed an ACE inhibitor are typically counseled about effective contraception, and prescribers should have a plan to switch medications quickly if pregnancy occurs.

Bilateral Renal Artery Stenosis

When both arteries supplying the kidneys are narrowed, ACE inhibitors can cause a dangerous drop in kidney function. The reason is mechanical. In a kidney with a restricted blood supply, the body compensates by constricting the tiny outflow vessels (efferent arterioles) at the end of each filtering unit to keep pressure high enough for filtration to happen. Angiotensin II is the hormone responsible for that constriction. ACE inhibitors remove angiotensin II from the equation, those outflow vessels relax, filtering pressure plummets, and the kidneys can effectively shut down.

This makes bilateral renal artery stenosis a recognized contraindication for ACE inhibitors due to the risk of acute kidney failure from preferential efferent arteriolar vasodilation.⁴ The same concern applies to someone with a single functioning kidney that has a stenosed artery, since they have no backup kidney to compensate. If the stenosis is only on one side and the other kidney’s artery is healthy, the risk is much lower, though prescribers still monitor kidney function closely after starting the drug.

Severe Aortic Stenosis and the Risk of Hypotension

ACE inhibitors lower blood pressure by reducing the resistance that blood encounters as it flows through the body’s arteries. In most people that is a good thing, but in someone whose aortic valve is severely narrowed, the heart is already struggling to push blood through a tight opening. Dropping the pressure on the other side of that valve can lead to dangerously low blood pressure, fainting, or worse. For this reason, ACE inhibitors have traditionally been avoided in patients with severe, symptomatic aortic stenosis because of the risk of hypotension.⁵

First-dose hypotension is a concern even outside of aortic stenosis. When captopril was first studied, researchers found that patients who were already salt- or volume-depleted (often from diuretic use) could develop significant drops in blood pressure, orthostatic lightheadedness, and even fainting after the very first dose.⁶ This is why prescribers often start at a low dose and recommend the first pill be taken at bedtime, especially in patients who are already on diuretics or have heart failure. It is not a permanent contraindication, but it does mean the drug needs to be introduced carefully in anyone at risk for low blood pressure.

Hyperkalemia and Kidney Disease

ACE inhibitors reduce the body’s production of aldosterone, a hormone that normally helps the kidneys excrete potassium. Less aldosterone means potassium builds up in the blood. For most healthy people this effect is minor, but in people with existing kidney problems or elevated baseline potassium, it can become dangerous. Potassium levels that climb too high disrupt the heart’s electrical rhythm and can trigger fatal cardiac arrhythmias.

A study looking at the timing of hyperkalemia after ACE inhibitor or ARB initiation found that the risk was sharply elevated in patients with chronic renal failure. At the potassium threshold of 5.5 mEq/L, hyperkalemia was nearly six times more likely in patients with chronic kidney disease, and at the more severe 6.0 mEq/L threshold, the risk was about nine times higher.⁷ The finding that stood out from that study was that hyperkalemia could appear at any point during the first two weeks, with no predictable peak day, so early and ongoing lab monitoring is necessary.

There is an interesting wrinkle in the advanced kidney disease population. ACE inhibitors have long been considered risky as kidneys deteriorate, and many prescribers stop them when kidney function drops very low. But a trial published in the New England Journal of Medicine enrolled over 400 patients with advanced chronic kidney disease and compared those who discontinued their ACE inhibitor or ARB against those who continued. After three years, the patients who stopped did not see a meaningful difference in kidney function compared to those who stayed on the drug, and if anything, the group that discontinued had a numerically higher rate of progressing to end-stage kidney disease or needing dialysis.⁸ The finding did not reach statistical significance, but it suggests that reflexively stopping ACE inhibitors in advanced kidney disease may not always be the right call. The decision needs to balance the hyperkalemia risk against the potential cardiovascular and renal protective benefits, ideally with frequent potassium monitoring.

Drug Interactions That Create Real Danger

Several commonly prescribed drug classes interact with ACE inhibitors in ways that deserve attention. Some create outright contraindications; others demand careful monitoring.

The Sacubitril/Valsartan Washout

Sacubitril/valsartan is a combination drug that has become a standard treatment for heart failure with reduced ejection fraction. It must never be given at the same time as an ACE inhibitor because the two together dramatically increase the risk of angioedema. If you are switching from an ACE inhibitor to sacubitril/valsartan, a 36-hour washout period is required after the last ACE inhibitor dose before starting the new drug.⁹ The same washout applies to aliskiren, a direct renin inhibitor. This is not a soft guideline: combining them is listed as a contraindication.²

Potassium-Sparing Diuretics

Because ACE inhibitors already raise potassium levels, adding a potassium-sparing diuretic like spironolactone, eplerenone, or amiloride compounds the risk. Coadministration can result in clinically significant hyperkalemia, especially in patients with impaired kidney function.¹⁰ That said, this combination is not absolutely prohibited. In severe heart failure, the survival benefits of adding spironolactone to an ACE inhibitor can outweigh the potassium risk. Data from a large international trial indicated that potassium-sparing diuretics could be given alongside ACE inhibitors as long as serum potassium was monitored closely, though a small number of patients had to stop because of dangerously high potassium levels.¹¹

NSAIDs and the “Triple Whammy”

Taking an ACE inhibitor alongside a diuretic and a nonsteroidal anti-inflammatory drug like ibuprofen or naproxen is known in clinical pharmacology as the “triple whammy.” Each drug individually affects the kidney’s ability to regulate blood flow and filtration, and together they can push a vulnerable patient into acute kidney injury.¹² The combination of any two of these three drug classes increases the risk, but having all three on board at once is particularly dangerous.¹³ This is especially relevant for older adults who may be on an ACE inhibitor for blood pressure, a diuretic for fluid retention, and who reach for over-the-counter ibuprofen for joint pain without realizing the combination is a problem.

Lithium

ACE inhibitors reduce the kidney’s ability to clear lithium, the drug used as a mood stabilizer in bipolar disorder. When an ACE inhibitor is added to a lithium regimen, lithium levels can climb into the toxic range. Case reports have documented serious lithium toxicity precipitated by the addition of an ACE inhibitor, with symptoms ranging from tremor and confusion to cardiac conduction abnormalities.¹⁴ If the combination is necessary, lithium levels need to be rechecked after starting the ACE inhibitor and monitored more frequently.

Hemodialysis with Certain Membrane Types

This is one of the more obscure contraindications, but it matters if you are on dialysis. Patients taking ACE inhibitors who undergo hemodialysis using polyacrylonitrile (AN69) membranes have experienced life-threatening anaphylactoid reactions within the first minutes of dialysis sessions. The reactions involve flushing, severe hypotension, and airway compromise. Researchers identified five such life-threatening episodes in three patients and determined that the reactions were likely caused by massive bradykinin accumulation from two simultaneous sources: the AN69 membrane itself triggers bradykinin production when blood contacts it, and the ACE inhibitor blocks the enzyme that would normally break bradykinin down.⁶

Subsequent research confirmed the bradykinin mechanism using a bradykinin receptor blocker, which prevented the reactions entirely in an animal model, and showed that the severity of reactions increased with the ACE inhibitor dose.¹⁵ The practical solution is straightforward: if you need an ACE inhibitor and also need dialysis, the dialysis unit uses a different membrane type. But the interaction is worth knowing about because it occasionally catches providers off guard, particularly when a patient already established on an ACE inhibitor starts dialysis at a facility that still uses AN69 membranes.

The Persistent Cough Problem

A dry, hacking cough is not technically a contraindication, but it is the single most common reason people stop taking ACE inhibitors. It affects a substantial minority of users and can be severe enough to disrupt sleep and daily life. The cough stems from the same bradykinin accumulation that causes angioedema, though the cough pathway involves bradykinin and substance P irritating sensory nerve fibers in the airways and triggering bronchoconstriction.¹⁶ The accumulated bradykinin sensitizes rapidly adapting stretch receptors and C-fiber receptors in the airways, which release additional inflammatory mediators that perpetuate the cough reflex.¹⁷

The cough can appear weeks or even months after starting the drug, which sometimes makes it hard for patients to connect it to their medication. It resolves after stopping the ACE inhibitor, though that can take days to weeks. For patients who develop this side effect, the typical switch is to an angiotensin receptor blocker (ARB), which lowers blood pressure through a related but different mechanism and does not cause bradykinin accumulation. ARBs share many of the same contraindications as ACE inhibitors (pregnancy, bilateral renal artery stenosis, hyperkalemia risk), but the cough and angioedema rates are much lower.

Who Carries the Highest Risk of Adverse Effects

Adverse events from ACE inhibitors are not evenly distributed across the population. Analysis of the FDA’s adverse event reporting system found that adverse drug events were disproportionately higher in adults and elderly patients compared to those under 18. The most commonly reported problems were angioedema, cough, hypotension, and acute kidney injury.¹⁸ Older adults face a higher burden partly because they are more likely to have the conditions that amplify ACE inhibitor risks: diminished kidney function, volume depletion from diuretics, and polypharmacy that introduces interactions.

Pediatric cases, while less common, remain clinically relevant for specific ACE inhibitor agents. Children prescribed these drugs for conditions like kidney disease or heart failure require the same careful monitoring for hyperkalemia and renal function as adults, scaled to their physiology.

What You Use Instead

When an ACE inhibitor is contraindicated or intolerable, the first-line alternative for most indications is an ARB. The two drug classes target the same hormonal system from different angles, and ARBs carry a much lower risk of cough and angioedema. However, ARBs share the contraindications related to pregnancy, bilateral renal artery stenosis, and hyperkalemia, so they are not always the answer either.

For heart failure specifically, if both ACE inhibitors and ARBs are off the table, the combination of hydralazine and a nitrate has demonstrated long-term benefits and remains a rational alternative.¹⁹ This combination works through an entirely different vasodilatory pathway and avoids the bradykinin-related side effects altogether. It is particularly well studied in patients who cannot tolerate renin-angiotensin system blockers of any kind. For blood pressure management alone, the choices are broader: calcium channel blockers, thiazide diuretics, and beta-blockers all serve as effective alternatives depending on the patient’s other medical conditions.

A Bradykinin Thread Runs Through Most of the Risks

If you look at the list of ACE inhibitor contraindications and major side effects as a whole, one molecule keeps showing up. Bradykinin accumulation, a direct and unavoidable consequence of blocking the ACE enzyme, is the mechanism behind the cough, the angioedema, and the anaphylactoid reactions during dialysis with AN69 membranes. It also plays a role in the first-dose hypotension some patients experience. This is not a flaw in a particular ACE inhibitor formulation; it is built into the way the entire drug class works. The enzyme that converts angiotensin I into angiotensin II is the same enzyme that breaks down bradykinin. You cannot block one function without affecting the other.

Understanding this helps explain why switching between different ACE inhibitors rarely solves a side effect. A cough from lisinopril will almost certainly recur with enalapril or ramipril because they all inhibit the same enzyme. It also explains why ARBs, which block the angiotensin II receptor instead of blocking ACE itself, do not cause the same bradykinin-related problems. They leave the bradykinin degradation pathway intact. For people who need renin-angiotensin system blockade but cannot tolerate the bradykinin consequences, that mechanistic difference is what makes an ARB the logical next step rather than simply trying a different ACE inhibitor.